AOD-9604 Dosing Protocols Based on Clinical Research Dosing recommendations for AOD-9604 are based on extensive human research including six clinical trials that evaluated various administration routes, doses, and treatment durations
In contrast, vancomycin, which does not penetrate mammalian cells, had no effect
Unlike pharmacological interventions that target single receptors or pathways, GHK-Cus multi-gene modulation touches many of the hallmarks of aging simultaneously: Genomic instability (DNA repair gene upregulation) Epigenetic alterations (chromatin remodeling via altered transcription factor activity) Loss of proteostasis (chaperone and proteasome pathway modulation) Cellular senescence (anti-apoptotic and anti-senescence gene networks) Altered intercellular communication (anti-inflammatory cytokine modulation) This positions GHK-Cu within what researchers increasingly call multi-hallmark peptide therapy a conceptual framework that prioritizes compounds acting across multiple aging mechanisms simultaneously
GH-supporting peptides (Sermorelin, Tesamorelin, CJC/Ipamorelin) include IGF-1 and a metabolic panel
But I think this is, is like kind of the question
We don't know what's in them